全文获取类型
收费全文 | 812篇 |
免费 | 36篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 39篇 |
妇产科学 | 3篇 |
基础医学 | 62篇 |
口腔科学 | 9篇 |
临床医学 | 62篇 |
内科学 | 223篇 |
皮肤病学 | 3篇 |
神经病学 | 5篇 |
特种医学 | 313篇 |
外科学 | 48篇 |
综合类 | 19篇 |
预防医学 | 22篇 |
眼科学 | 3篇 |
药学 | 31篇 |
中国医学 | 1篇 |
肿瘤学 | 26篇 |
出版年
2022年 | 1篇 |
2021年 | 9篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 8篇 |
2014年 | 8篇 |
2013年 | 8篇 |
2012年 | 13篇 |
2011年 | 19篇 |
2010年 | 12篇 |
2009年 | 19篇 |
2008年 | 14篇 |
2007年 | 36篇 |
2006年 | 16篇 |
2005年 | 15篇 |
2004年 | 9篇 |
2003年 | 6篇 |
2002年 | 10篇 |
2001年 | 9篇 |
2000年 | 4篇 |
1999年 | 17篇 |
1998年 | 46篇 |
1997年 | 42篇 |
1996年 | 57篇 |
1995年 | 43篇 |
1994年 | 33篇 |
1993年 | 39篇 |
1992年 | 9篇 |
1991年 | 10篇 |
1990年 | 10篇 |
1989年 | 31篇 |
1988年 | 35篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 39篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 24篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 26篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1969年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有870条查询结果,搜索用时 468 毫秒
51.
Richard Culleton 《Acta tropica》2010,114(3):131-137
The intracellular trafficking of an Erythrocyte Binding Like (EBL) ligand has recently been shown to dramatically affect the multiplication rate and virulence of the rodent malaria parasite Plasmodium yoelii yoelii. In this review, we describe the current understanding of the role of EBL and other erythrocyte binding ligands in erythrocyte invasion, and discuss the mechanisms by which they may control multiplication rates and virulence in malaria parasites. 相似文献
52.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
53.
54.
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy 总被引:1,自引:0,他引:1
McAlister FA Zarnke KB Campbell NR Feldman RD Levine M Mahon J Grover SA Lewanczuk R Leenen F Tobe S Lebel M Stone J Schiffrin EL Rabkin SW Ogilvie RI Larochelle P Jones C Honos G Fodor G Burgess E Hamet P Herman R Irvine J Culleton B Wright JM;Canadian Hypertension Recommendations Working Group 《The Canadian journal of cardiology》2002,18(6):625-641
OBJECTIVE: To provide updated, evidence-based recommendations for the therapy of hypertension in adults. OPTIONS: For patients with hypertension, a number of antihypertensive agents may control blood pressure. Randomized trials evaluating first-line therapy with thiazides, beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, alpha-blockers, centrally acting agents or angiotensin II receptor antagonists were reviewed. OUTCOMES: The health outcomes that were considered were changes in blood pressure, cardiovascular morbidity, and cardiovascular and/or all-cause mortality rates. Economic outcomes were not considered due to insufficient evidence. EVIDENCE: MEDLINE was searched for the period March 1999 to October 2001 to identify studies not included in the 2000 revision of the Canadian Recommendations for the Management of Hypertension. Reference lists were scanned, experts were polled, and the personal files of the subgroup members and authors were used to identify other published studies. All relevant articles were reviewed and appraised, using prespecified levels of evidence, by content experts and methodological experts. VALUES: A high value was placed on the avoidance of cardiovascular morbidity and mortality. BENEFITS, HARMS AND COSTS: Various antihypertensive agents reduce the blood pressure of patients with sustained hypertension. In certain settings, and for specific classes of drugs, blood-pressure lowering has been associated with reduced cardiovascular morbidity and/or mortality. RECOMMENDATIONS: The present document contains detailed recommendations pertaining to treatment thresholds, target blood pressures, and choice of agents in various settings in patients with hypertension. The main changes from the 2000 Recommendations are the addition of a section on the treatment of hypertension in patients with diabetes mellitus, the amalgamation of the previous sections on treatment of hypertension in the young and old into one section, increased emphasis on the role of combination therapies over repeated trials of single agents and expansion of the section on the treatment of hypertension after stroke. Implicit in the recommendations for therapy is the principle that treatment for an individual patient should take into consideration global cardiovascular risk, the presence and/or absence of target organ damage, and comorbidities. VALIDATION: All recommendations were graded according to strength of the evidence and voted on by the Canadian Hypertension Recommendations Working Group. Individuals with potential conflicts of interest relative to any specific recommendation were excluded from voting on that recommendation. Only those recommendations achieving high levels of consensus are reported here. These guidelines will continue to be updated annually. 相似文献
55.
56.
57.
Lindberg JS Culleton B Wong G Borah MF Clark RV Shapiro WB Roger SD Husserl FE Klassen PS Guo MD Albizem MB Coburn JW 《Journal of the American Society of Nephrology : JASN》2005,16(3):800-807
Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH > or =300 pg/ml despite traditional therapy. A total of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH (iPTH) level of < or =250 pg/ml. During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduction outcomes, including proportion of patients with mean iPTH levels < or =300 pg/ml (46 versus 9%), proportion of patients with > or =30% reduction in iPTH from baseline (65 versus 13%), and proportion of patients with > or =20, > or =40, or > or =50% reduction from baseline. Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH < or =300 pg/ml. Cinacalcet also significantly reduced serum calcium, phosphorus, and Ca x P levels compared with control treatment. The most common side effects, nausea and vomiting, were usually mild to moderate in severity and transient. Once-daily oral cinacalcet was effective in rapidly and safely reducing PTH, Ca x P, calcium, and phosphorus levels in patients who received HD or PD. Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. 相似文献
58.
59.
60.
Multispectral analysis of magnetic resonance images 总被引:1,自引:0,他引:1
Magnetic resonance (MR) imaging systems produce spatial distribution estimates of proton density, relaxation time, and flow, in a two dimensional matrix form that is analogous to that of the image data obtained from multispectral imaging satellites. Advanced NASA satellite image processing offers sophisticated multispectral analysis of MR images. Spin echo and inversion recovery pulse sequence images were entered in a digital format compatible with satellite images and accurately registered pixel by pixel. Signatures of each tissue class were automatically determined using both supervised and unsupervised classification. Overall tissue classification was obtained in the form of a theme map. In MR images of the brain, for example, the classes included CSF, gray matter, white matter, subcutaneous fat, muscle, and bone. These methods provide an efficient means of identifying subtle relationships in a multi-image MR study. 相似文献